In summary, while many questions remain to be addressed, it is clear that reducing chronic stress or the use of β-AR blockades could be an exciting new therapeutic strategy to reduce immunosuppression and increase radiosensitivity and thus be of great benefit to patients who will receive radiotherapy for the treatment of cancer. Here, ADRB2 is linked to cancer.